ADVERSE DRUG EVENT REPORTING OF REMDESIVIR

Gawali Vijay Appu; Dipak A. Joshi; Shyamlila B. Bavage; Nandkishor B. Bavage

ADVERSE DRUG EVENT REPORTING OF REMDESIVIR

Authors: Gawali Vijay Appu, Dipak A. Joshi, Shyamlila B. Bavage, Nandkishor B. Bavage

Unique Paper ID: 152387
Volume: 8
Issue: 3
PageNo: 159-161

Keywords: No Keywords Found

Abstract:
Purpose; Remdesivir shows promise in the treatment of COVID19 patients. Despite this, it is still necessary to record potential drug side effects (PBL) for future decision-making. Same as the limited ADE data available before the COVID19 pandemic.

Download article

email to a friend

Cite This Article

ISSN: 2349-6002
Volume: 8
Issue: 3
PageNo: 159-161

ADVERSE DRUG EVENT REPORTING OF REMDESIVIR

Available:https://ijirt.org/Article?manuscript=152387

09 Nov, 2021

REVIEW ON DIABETES MELLITUS

17 Oct, 2021

DRUG REPURPOSING IN ANTIVIRAL RESEARCH: A REVIEW

08 Aug, 2021

RHINO-ORBITAL MUCORMYCOSIS ASSOCIATED WITH COVID-19

08 Aug, 2021

THE PRINCIPLES OF SKIN TISSUE ENGINEERING

08 Aug, 2021

A REVIEW ON LYME BORRELIOSIS

31 Jul, 2021

AWARENESS ABOUT BANNED DRUG

31 Jul, 2021

APPLICATION AND THE PRODUCTION OF RADIOPHARMACEUTICAL’S

30 Jul, 2021

ANTHELMINTIC ACTIVITY OF SOME MEDICINAL PLANTS

30 Jul, 2021

A REVIEW ON DRUMSTICK PLANTS (MORINGA OLEIFERA) MEDICAL USES AND NUTRITIONAL PROPERTIES

29 Jul, 2021

PHARMACOTHERAY OF HYPERTENSION

Impact Factor
8.01 (Year 2024)

UGC Approved
Journal no 47859

Join Our IPN

IJIRT Partner Network

Submit your research paper and those of your network (friends, colleagues, or peers) through your IPN account, and receive 800 INR for each paper that gets published.

Join Now

Latest Publication

Recent Conferences

NCSEM 2024

National Conference on Sustainable Engineering and Management - 2024 Last Date: 15th March 2024

Submit inquiry